🕔11/4/2008 7:27:00 PM
Biotec Pharmacon ASA (OSL:BIOTEC) The first 3 patients have been enrolled in the second of Biotec Pharmacon's two phase III-studies with SBG for treatment of diabetic ulcers. An estimated 3.5 million diabetes patients in the OECD-area annually develop foot and leg ulcers, for which there are no well-established treatments available. These ulcers often develop into a chronic condition with high risk of infections, which in many cases may end with amputation. Results from Biotec Pharmacon's first phase III-study is expected during 2009, and the company targets filing for marketing authorisations for SBG for this indication mid-2010.
Read Full Article▸